Skip to main content
SpringerLink
Log in

The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: Meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC)

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC) were carried out in 6 regions of Japan from 1982 to 1985, and the results were subjected to meta-analysis.

Subjects consisted of Stage II and IIIa cases who underwent radical mastectomy with Brt + Ax or more extensive resection for primary breast cancer.

Regimen A consisted of tegafur (Futraful: FT) alone at 600 mg/day, and regimen B of FT at 600 mg/day with tamoxifen (TAM) at 20 mg/day. The duration of the treatment was one year in the Tohoku and Kinki regions, and 2 years in the other 4 regions.

Meta-analysis by Peto’s method showed an odds reduction of 20 ± 7% (logrank test:P = 0.0069) for the 5-year overall survival rate in 4740 eligible patients, and 25 ± 6% (logrank test: P>0.0001) for the 5-year disease-free survival rate. The odds reductions were both statistically significant, indicating that the adjuvant chemoendocrine therapy was effective. Subset analysis of data on 5 - year disease-free survival showed that FT plus TAM therapy was better in ER-positive and postmenopausal patients, whether axillary lymph nodes were positive or negative.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ACETBC:

Adjuvant chemoendocrine therapy for breast cancer

ADR:

Adriamycin

CAF:

CycIophosphamide, adriamycin, 5-FU

CMF:

Cyclophosphamide, methotrexate, 5-FU

CPA:

Cyclophosphamide

ER:

Estrogen receptors

FT:

Tegafur(Futraful)

MMC:

Mitomycin C

TAM:

Tamoxifen

References

  1. Yoshida M, Murai H, Miura S: Post-operative chemotherapy with oral cyclophosphamide in breat cancer (UICC 73-047).J Jap Soc Cancer Ther 18 (8):2166, 1982.

    Google Scholar 

  2. Yamase H, Akita Y, Takaesu Y,et al: Long term results of post-operative adjuvant chemotherapy with mitomycin C in breast cancer.J Jap Soc Cancer Ther 17 (8):2115, 1982.

    Google Scholar 

  3. Koyama H, Wada T, Takahashi T,et al: Surgical adjuvant chemotherapy with mitomycin C and cyclophospamide in Japanese patients with breast cancer.Cancer 46:343–348, 1980.

    Article  Google Scholar 

  4. Ansfield F, Kallas GJ, Sington JP: Phase I -II studies of oral tegafur (ftorafur).J Clin Oncol 1:107–110, 1983.

    PubMed  CAS  Google Scholar 

  5. Adachi I: Endocrine therapy for advanced breast cancer evaluated by the site of metastasis; Therapeutic results of chemotherapy and life prolonging effect.Jpn J Cancer Chemother 8(Suppl):72–78, 1981.

    Google Scholar 

  6. Chikada C, Niitani H, Sakauchi N,et al: Oral treatment withN 1-(2’-furanidyl)-5-fluorouracil (FT-207).Jpn J Cancer Clin 19:435–439, 1973.

    Google Scholar 

  7. Wada T, Koyama H, Nishizawa M,et al: Chemoendocrine therapy in advanced breast cancer; Combined therapy with tamoxifen plus FT 207.J Jap Soc Cancer Ther 16 (1):51–55, 1981.

    CAS  Google Scholar 

  8. Buyse M: Potential and pitfalls of randomized clinical trials in cancer research.Cancer Surv 8:91–105, 1989.

    PubMed  CAS  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71–85, 1992.

    Google Scholar 

  10. Sakamoto G: Characteristics and future of breast cancer in Japanese population.Jpn J Breast Cancer 2 (3):327–338, 1987.

    Google Scholar 

  11. Early Breast Cancer Trialists’ Collaborative Group: Treatment of early breast cancer, Vol. 1; Worldwide evidence, 1985–1990, Oxford University Press, Oxford, 1990.

    Google Scholar 

  12. Glick JH: Meeting highlights; Adjuvant therapy for breast cancer.J NCI 84:1479–1485, 1992.

    CAS  Google Scholar 

  13. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen.Pharmacol Ther 25:127–205, 1984.

    Article  PubMed  CAS  Google Scholar 

  14. Abe O, Izuo M, Enomoto K,et al: Study of adriamycin in advanced and recurrent breast cancer, Part 2; Multicentered clinical study of CAF therapy in 18 medical centers.Jpn J Cancer Chemother 9 (5):866–873, 1982.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sr Luke’s International Hospital, 10-1, Akashi-machi, Chuo-ku, Tokyo 104, Japan

    Osahiko Abe

Authors
  1. Osahiko Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Abe, O. The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: Meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC). Breast Cancer 1, 1–9 (1994). https://doi.org/10.1007/BF02967368

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967368

Key words

Search

Navigation